EP 1047457 A2 20001102 - USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
Title (en)
USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
Title (de)
RADIOMARKIERTE MONOKLONES IGM ZÜR THERAPIE VON KREBS UND AUTOIMMUNKRANKHEIT
Title (fr)
IMMUNOGLOBULINE M MONOCLONALE RADIOMARQUEE DESTINEE AU TRAITEMENT DU CANCER ET D'UNE MALADIE AUTO-IMMUNE
Publication
Application
Priority
- US 9900857 W 19990115
- US 862098 A 19980116
Abstract (en)
[origin: WO9936105A2] It has been discovered that large antibody aggregates or molecules, such as IgM or conjugated IgG or IgG fusion proteins, can be used to treat tumors by intracompartmental or intratumoral administration of anti-tumor antibody coupled to a toxin. The method can also be used in the treatment of certain disorders characterized by deposition of immune complex, for example, rheumatoid arthritis. In the preferred embodiment, the antibody is IgM and the toxin is a radioisotope, most preferably <111>In-labelled IgM or <90>Y-labelled IgM. Examples demonstrate effectiveness in mice models.
IPC 1-7
IPC 8 full level
A61K 39/395 (2006.01); A61K 47/48 (2006.01); A61K 51/00 (2006.01); A61K 51/10 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); A61K 103/32 (2006.01)
CPC (source: EP)
A61K 47/6869 (2017.07); A61K 51/1093 (2013.01); A61K 51/1096 (2013.01); A61P 35/00 (2017.12); A61P 37/02 (2017.12)
Citation (search report)
See references of WO 9936105A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9936105 A2 19990722; WO 9936105 A3 20000210; WO 9936105 A9 19991021; AU 3544599 A 19990802; CA 2318231 A1 19990722; EP 1047457 A2 20001102; JP 2002509122 A 20020326
DOCDB simple family (application)
US 9900857 W 19990115; AU 3544599 A 19990115; CA 2318231 A 19990115; EP 99917293 A 19990115; JP 2000539876 A 19990115